Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Angiogenesis inhibition, hypoxia, and targeting the bone marrow microenvironment in multiple myeloma: new strategies and targets

Angiogenesis inhibition, hypoxia, and targeting the bone marrow microenvironment in multiple... Multiple myeloma (MM) is a hematological B-cell malignancy that has still a fatal prognosis. Although the treatments have improved, one major problem in MM is the clinical resistance to available drugs and combination therapies over time. Novel agents, such as oral proteasome inhibitors, monoclonal antibodies, second generation immunomodulatory drugs and therapies targeting the cell signaling and the tumor microenvironment are in development for the treatment of relapsed/refractory MM. In this review, we refer on the role of new strategies targeting the tumor microenvironment, especially on angiogenesis, hypoxia and other interactions between MM and bone marrow components. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Angiogenesis inhibition, hypoxia, and targeting the bone marrow microenvironment in multiple myeloma: new strategies and targets

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/angiogenesis-inhibition-hypoxia-and-targeting-the-bone-marrow-CjT5GcUYoA
Publisher
Springer Journals
Copyright
Copyright © 2014 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-014-0184-2
Publisher site
See Article on Publisher Site

Abstract

Multiple myeloma (MM) is a hematological B-cell malignancy that has still a fatal prognosis. Although the treatments have improved, one major problem in MM is the clinical resistance to available drugs and combination therapies over time. Novel agents, such as oral proteasome inhibitors, monoclonal antibodies, second generation immunomodulatory drugs and therapies targeting the cell signaling and the tumor microenvironment are in development for the treatment of relapsed/refractory MM. In this review, we refer on the role of new strategies targeting the tumor microenvironment, especially on angiogenesis, hypoxia and other interactions between MM and bone marrow components.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Nov 13, 2014

References

  • Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010
    Lozano, R; Naghavi, M; Foreman, K; Lim, S; Shibuya, K; Aboyans, V
  • Multiple myeloma therapies
    Strobeck, M
  • Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
    Kumar, SK; Dispenzieri, A; Lacy, MQ; Gertz, MA; Buadi, FK; Pandey, S
  • Approach to the treatment of multiple myeloma: a clash of philosophies
    Rajkumar, SV; Gahrton, G; Bergsagel, PL
  • Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt Inhibitor Dkk1
    Fowler, JA; Mundy, GR; Lwin, ST; Edwards, CM
  • Immunological dysregulation in multiple myeloma microenvironment
    Romano, A; Conticello, C; Cavalli, M; Vetro, C; La Fauci, A; Parrinello, NL
  • The role of microenvironment in tumor angiogenesis
    Ribatti, D; Vacca, A
  • Cell trafficking of endothelial progenitor cells in tumor progression
    la, Puente P; Muz, B; Azab, F; Azab, AK
  • Bone marrow angiogenesis in multiple myeloma
    Vacca, A; Ribatti, D
  • Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood
    Di Raimondo, F; Azzaro, MP; Palumbo, G; Bagnato, S; Giustolisi, G; Floridia, P
  • Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment
    Du, W; Hattori, Y; Hashiguchi, A; Kondoh, K; Hozumi, N; Ikeda, Y
  • Mechanism of action of lenalidomide in hematological malignancies
    Kotla, V; Goel, S; Nischal, S; Heuck, C; Vivek, K; Das, B
  • Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma
    Kumar, S; Witzig, TE; Dispenzieri, A; Lacy, MQ; Wellik, LE; Fonseca, R
  • Phase II Study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma
    Zangari, M; Anaissie, E; Stopeck, A; Morimoto, A; Tan, N; Lancet, J
  • GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment
    Podar, K; Catley, LP; Tai, YT; Shringarpure, R; Carvalho, P; Hayashi, T
  • A phase II study of ZD6474 (Zactima), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145
    Kovacs, M; Reece, D; Marcellus, D; Meyer, R; Mathews, S; Dong, RP
  • Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034)
    Prince, HM; Hönemann, D; Spencer, A; Rizzieri, DA; Stadtmauer, EA; Roberts, AW
  • Bevacizumab: current updates in treatment
    Meter, ME; Kim, ES
  • Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial
    Somlo, G; Lashkari, A; Bellamy, W; Zimmerman, TM; Tuscano, JM; O'Donnell, MR
  • Phase II trial of bevacizumab combined with low dose dexamethasone and lenalidomide (BEV/REV/DEX) for relapsed or refractory myeloma (MM)
    Raschko, M; Markovina, S; Miyamoto, S; Longo, W; Williams, E; McFarland, T
  • Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features
    Azab, AK; Hu, J; Quang, P; Azab, F; Pitsillides, C; Awwad, R
  • Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma
    Alsayed, Y; Ngo, H; Runnels, J; Leleu, X; Singha, UK; Pitsillides, CM
  • CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
    Azab, AK; Runnels, JM; Pitsillides, C; Moreau, AS; Azab, F; Leleu, X
  • HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target
    Ria, R; Catacchio, I; Berardi, S; De Luisi, A; Caivano, A; Piccoli, C
  • Hypoxia-inducible factor (HIF)-1alpha suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction
    Storti, P; Bolzoni, M; Donofrio, G; Airoldi, I; Guasco, D; Toscani, D
  • P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment
    Azab, AK; Quang, P; Azab, F; Pitsillides, C; Thompson, B; Chonghaile, T
  • Adhesive interactions of human multiple myeloma cell lines with different extracellular matrix molecules
    Kibler, C; Schermutzki, F; Waller, HD; Timpl, R; Muller, CA; Klein, G
  • CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q
    Liebisch, P; Eppinger, S; Schopflin, C; Stehle, G; Munzert, G; Dohner, H
  • Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells
    Roccaro, AM; Hideshima, T; Raje, N; Kumar, S; Ishitsuka, K; Yasui, H
  • GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib
    Kern, J; Untergasser, G; Zenzmaier, C; Sarg, B; Gastl, G; Gunsilius, E
  • Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma
    Caers, J; Menu, E; De Raeve, H; Lepage, D; Valckenborgh, E; Van Camp, B
  • Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo
    Mitsiades, CS; Ocio, EM; Pandiella, A; Maiso, P; Gajate, C; Garayoa, M
  • Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4
    Broggini, M; Marchini, SV; Galliera, E; Borsotti, P; Taraboletti, G; Erba, E
  • Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis
    Deryugina, EI; Quigley, JP